Human papillomavirus genotype distribution and socio-behavioural characteristics in women with cervical pre-cancer and cancer at the start of a human papillomavirus vaccination programme: the CIN3+ plus study.
Details
Serval ID
serval:BIB_5C2CE1B9A651
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Human papillomavirus genotype distribution and socio-behavioural characteristics in women with cervical pre-cancer and cancer at the start of a human papillomavirus vaccination programme: the CIN3+ plus study.
Journal
BMC cancer
Working group(s)
CIN3+plus study group
Contributor(s)
Baege A., Bannwart F., Berlin C., Cassinotti P., Cathomas G., Claass J., Eklund C., Frattini M., Graber A., Häfliger A., Ho L., Kind A., Kreis C., Mazzucchelli L., McKee T., Megevand E., Meyer-Hamme U., Molinari F., Noppen C., Noske A., Raineri I., Rapiti E., Rubi D., Rupp N.J., Schwedler K., Stallmach T., Tille J.C., Tornillo L., Valera A., Weintraub D., Went P., Zimmermann D.
ISSN
1471-2407 (Electronic)
ISSN-L
1471-2407
Publication state
Published
Issued date
30/01/2019
Peer-reviewed
Oui
Volume
19
Number
1
Pages
111
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Publication Status: epublish
Abstract
The Swiss Federal Office of Public Health has recommended vaccination against human papillomavirus (HPV) to prevent cervical cancer since 2008. To establish monitoring of the future public health impact of vaccination, baseline population-based data are required. The objectives of this study were to examine the distribution of oncogenic HPV genotypes in biopsies with cervical intraepithelial neoplasia stage 3 or more severe lesions (CIN3+) at the beginning of HPV vaccination programmes and to compare sociodemographic and behavioural factors of women with CIN3+ with women in the Swiss general population.
We conducted a retrospective and prospective cross-sectional study with women diagnosed with CIN3+ in Switzerland. Ten pathology institutes from six cantons and three language regions participated. We conducted HPV typing on formaldehyde fixed-paraffin embedded specimens from 2014 and 2015. Women enrolled in 2015 were asked to complete a questionnaire. We described frequencies of HPV types. We also compared demographic characteristics and socioeconomic status in the CIN3 + plus group with the Swiss National Cohort in 2014 and compared risk factors for HPV infection with the Swiss Health Survey in 2012.
We included 768 biopsies from 767 women. Four hundred and seventy-five (61.8%) biopsies were positive for HPV 16 and/or 18, 687 (89.5%) were positive for oncogenic HPV genotypes 16, 18, 31, 33, 45, 52, and/or 58 and five (0.7%) were HPV negative. Twenty-eight (10.3%) of the 273 women who completed the patient questionnaire reported having received at least one dose of an HPV vaccine. When compared with Swiss women in the six study cantons, fewer women in the CIN3+ plus study group were of Swiss nationality, more were born abroad and more were single. The study group also had a higher proportion of women with ≥2 partners in the last year, current smokers and was younger at age of first sexual intercourse.
Introduction of the nonavalent vaccine could cover approximately 90% of CIN3+ lesions in Swiss women compared with around 60% with the quadrivalent vaccine. Surveillance of HPV genotype distribution in CIN3+, together with information about vaccination and CIN3+ incidence will allow monitoring of the public health impact of vaccination programmes.
ClinicalTrials.gov, NCT02323997 . Registered 24 December 2014.
We conducted a retrospective and prospective cross-sectional study with women diagnosed with CIN3+ in Switzerland. Ten pathology institutes from six cantons and three language regions participated. We conducted HPV typing on formaldehyde fixed-paraffin embedded specimens from 2014 and 2015. Women enrolled in 2015 were asked to complete a questionnaire. We described frequencies of HPV types. We also compared demographic characteristics and socioeconomic status in the CIN3 + plus group with the Swiss National Cohort in 2014 and compared risk factors for HPV infection with the Swiss Health Survey in 2012.
We included 768 biopsies from 767 women. Four hundred and seventy-five (61.8%) biopsies were positive for HPV 16 and/or 18, 687 (89.5%) were positive for oncogenic HPV genotypes 16, 18, 31, 33, 45, 52, and/or 58 and five (0.7%) were HPV negative. Twenty-eight (10.3%) of the 273 women who completed the patient questionnaire reported having received at least one dose of an HPV vaccine. When compared with Swiss women in the six study cantons, fewer women in the CIN3+ plus study group were of Swiss nationality, more were born abroad and more were single. The study group also had a higher proportion of women with ≥2 partners in the last year, current smokers and was younger at age of first sexual intercourse.
Introduction of the nonavalent vaccine could cover approximately 90% of CIN3+ lesions in Swiss women compared with around 60% with the quadrivalent vaccine. Surveillance of HPV genotype distribution in CIN3+, together with information about vaccination and CIN3+ incidence will allow monitoring of the public health impact of vaccination programmes.
ClinicalTrials.gov, NCT02323997 . Registered 24 December 2014.
Keywords
Adolescent, Adult, Aged, Aged, 80 and over, Cervical Intraepithelial Neoplasia/epidemiology, Cervical Intraepithelial Neoplasia/pathology, Cervical Intraepithelial Neoplasia/virology, Cross-Sectional Studies, Female, Genotype, Humans, Incidence, Middle Aged, Neoplasm Staging, Papillomaviridae/genetics, Papillomaviridae/isolation & purification, Papillomavirus Infections/epidemiology, Papillomavirus Infections/pathology, Papillomavirus Infections/virology, Papillomavirus Vaccines, Population Surveillance, Prospective Studies, Retrospective Studies, Risk Factors, Switzerland/epidemiology, Uterine Cervical Neoplasms/epidemiology, Uterine Cervical Neoplasms/pathology, Uterine Cervical Neoplasms/virology, Vaccination/statistics & numerical data, Young Adult, Cervical cancer, Cervical dysplasia, Cervical intraepithelial neoplasia, HPV, Human papillomavirus, Vaccines
Pubmed
Web of science
Open Access
Yes
Create date
25/03/2019 10:06
Last modification date
20/08/2019 15:14
Usage data
